Akari Therapeutics Plc financial data

Symbol
AKTX on Nasdaq
Industry
Pharmaceutical Preparations
Location
22 Boston Wharf Road, Fl 7, Boston, MA
State of incorporation
United Kingdom
Former names
Celsus Therapeutics Plc. (to 9/15/2015), Morria Biopharmaceuticals PLC (to 6/20/2013)
Latest financial report
8-K - Q2 2024 - Sep 6, 2024

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 23.9B shares
Common Stock, Shares, Outstanding 23.1M shares -99.8%
Entity Public Float 13.6M USD
Common Stock, Value, Issued 1.6M USD
Weighted Average Number of Shares Outstanding, Basic 23.1M shares +14.2%
Weighted Average Number of Shares Outstanding, Diluted 23.1M shares +14.2%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 0 USD
Research and Development Expense 109K USD -70.7%
General and Administrative Expense 1.28M USD -44.2%
Operating Income (Loss) -1.39M USD +47.9%
Nonoperating Income (Expense) -687K USD +79%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -2.08M USD +65%
Earnings Per Share, Basic -0.09 USD/shares +69%
Earnings Per Share, Diluted -0.09 USD/shares +69%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 236K USD +9.99%
Other Assets, Current 94K USD -49.6%
Assets, Current 1.33M USD -83.3%
Property, Plant and Equipment, Net 31.8K USD
Operating Lease, Right-of-Use Asset 0 USD -100%
Intangible Assets, Net (Excluding Goodwill) 14K USD -17.6%
Other Assets, Noncurrent 11.1K USD
Assets 1.43M USD -82.1%
Accounts Payable, Current 5.47M USD +431%
Accrued Liabilities, Current 4.4M USD +83.3%
Liabilities, Current 24M USD
Operating Lease, Liability, Noncurrent 0 USD -100%
Other Liabilities, Noncurrent 0 USD
Liabilities 24M USD +359%
Accumulated Other Comprehensive Income (Loss), Net of Tax 142K USD
Retained Earnings (Accumulated Deficit) -42.7M USD +80.6%
Stockholders' Equity Attributable to Parent -22.6M USD -16.9%
Liabilities and Equity 1.43M USD -82.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -4.04M USD +17.1%
Net Cash Provided by (Used in) Financing Activities 1.51M USD -52.9%
Common Stock, Shares Authorized 60M shares -99.8%
Common Stock, Shares, Issued 23.1M shares -99.8%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -2.54M USD -52%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 296K USD +7.8%
Deferred Tax Assets, Valuation Allowance 16M USD -44.5%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.19 pure
Deferred Tax Assets, Gross 16.1M USD -46.4%
Depreciation 0 USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -2.06M USD +65.2%
Property, Plant and Equipment, Gross 753K USD -11.2%
Operating Lease, Liability, Current 4.6M USD
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Deferred Tax Assets, Operating Loss Carryforwards 43M USD +33%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 19.9M USD
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 13K USD +1200%
Deferred Tax Assets, Net of Valuation Allowance 16M USD -44.5%
Share-based Payment Arrangement, Expense 0 USD -100%
Interest Expense 51K USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares